(Updated, 5:40 p.m.)
Ximedica announced Tuesday it has purchased the San Francisco-based Bridge Design, providing the Rhode Island-based medical technology development company with a West Coast hub.
Tivorsan Pharmaceuticals Inc. has named James E. Connolly CEO. The biotechnology company, which focuses on treating Duchenne Muscular Dystrophy and other neuromuscular disorders, also said that Connolly will serve as a member of its board.
The first two patients in IlluminOss Medical Inc.’s U.S. Lightfix clinical trial for the treatment of impending and pathologic fractures have been successfully treated at the Marshall University Joan C. Edwards School of Medicine.